Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.
about
The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic reviewCost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitusGetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling.Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament.A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.The food choice at work study: effectiveness of complex workplace dietary interventions on dietary behaviours and diet-related disease risk - study protocol for a clustered controlled trial.Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancerLife Years Lost Associated with Obesity-Related Diseases for U.S. Non-Smoking AdultsMathematical modelling in tobacco control research: protocol for a systematic reviewSample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluationsCost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic ReviewMinimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Consensus Statement on Electronic Health Predictive Analytics: A Guiding Framework to Address Challenges.Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.Public health economic evaluation of different European Union-level policy options aimed at reducing population dietary trans fat intake.When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.Decision-analytic models: current methodological challenges.Health economics and outcomes methods in risk-based decision-making for blood safety.How Qualitative Methods Can be Used to Inform Model Development.Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.Simulation as an ethical imperative and epistemic responsibility for the implementation of medical guidelines in health care.Cost-effectiveness of In-Home Cognitive Behavioral Therapy for low-income depressed mothers participating in early childhood prevention programs.Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.Developing WHO guidelines: Time to formally include evidence from mathematical modelling studies.Economic evaluation of HIV pre-exposure prophylaxis strategies: protocol for a methodological systematic review and quantitative synthesis.The economic case for precision medicine.Systematic review of pharmacoeconomic models for schizophreniaDo Economic Evaluations in Primary Care Prevention and the Management of Hypertension Conform to Good Practice Guidelines? A Systematic Review
P2860
Q26801751-E819C314-12D3-423C-9CF4-887DDEE8D293Q28600953-C592BCDD-5EA9-46BB-A5CD-D96D2368DFCAQ30248472-5EF2294B-4CEF-462D-9F85-C898B6760EC2Q30823226-9162EDBB-73D7-4DD9-84A9-554DBC93B458Q32966564-2589277B-2006-477B-9C2D-77BE46D06274Q33413196-FDD7D31F-29BC-4B72-B8EC-2D1562DEAFFFQ33646171-976F9684-AFDF-42DF-8F01-BE2FAC4C0CA9Q34492423-10CF14D6-A218-4ED6-9D81-489E7A827412Q34573853-8750D733-5F0C-4498-8DFD-F7C0792545FFQ34792656-B9335B04-B9B9-4509-A27D-A2860392493AQ35466086-EBC95B08-9067-47D3-BA40-4C78F5437B8DQ35664152-775D35EF-0EE6-45FC-811E-FDD0879D7F7EQ35665481-189F8151-7417-4515-BE29-59C274726EC8Q35930922-7CE324D8-4113-41DE-AF3D-483B4CE15A95Q36149920-9373FCED-F2F7-4BE0-BF70-6EED5435E452Q36731638-F05919BE-EB8D-4DCB-89B1-ACB2C8177044Q36816489-3552D383-C39E-44ED-9536-B4A174DC7F5AQ37098646-F90977A8-81DD-4C72-8CD8-D6C4714F13FDQ37369688-AC928306-7ABD-4C76-B6ED-195F08388089Q38195815-84686FBB-49BC-460B-BC7E-6B9537C9E55DQ38205728-5451D88E-0B14-46E1-9E11-B993CF38B4E7Q38225412-059CA889-F871-4E1C-8914-447FA89EC4F3Q38412277-50353460-ED1C-4B64-8735-DE5B0B545659Q38742573-1162E703-29B5-4D80-B172-FF27BA6C139FQ38743343-28F3389A-FC46-4DCC-A01D-BACBE0127EFCQ38755073-B1AC24D7-77DA-480A-9E07-ED48351C1F11Q38767961-A2A45230-74D1-4FE9-A5CA-71842FDB0A05Q38916928-A25DBE2C-26D7-4141-B627-3E0C5BF33CF3Q39609265-59996DA8-83C1-49CB-99B9-DB72C6F4E6D7Q42636265-3C746584-855C-4F96-8C17-A4467C60BF5DQ45055651-11BE342C-C0E9-4AF4-97E4-08FF72A9C10DQ47680879-5E1A3375-E0E7-4DD2-9883-42B05EB8911CQ48035843-6AD0971F-7026-422E-9DFB-E92507397E2FQ48246205-7DBFD575-EF96-47CA-A89E-B16C69EBD20EQ52646536-E10EE830-49E0-42A6-BDFC-D8B118D3DB35Q54255292-E6F69F08-CCC7-4EF0-B4D3-736E315A4BE1Q55217201-87908054-2DE6-4C7C-AD13-BE2127126370Q57169493-0748DC4B-5E0F-4F91-828E-90F94D753521Q57950390-9920C8F9-E5D4-46DC-91CC-0B3843D6DA40
P2860
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@ast
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@en
type
label
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@ast
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@en
prefLabel
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@ast
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@en
P2093
P2860
P1433
P1476
Conceptualizing a model: a rep ...... earch Practices Task Force--2.
@en
P2093
A David Paltiel
ISPOR-SMDM Modeling Good Research Practices Task Force
Louise B Russell
Mark Roberts
Michael Chambers
Phil McEwan
P2860
P304
P356
10.1016/J.JVAL.2012.06.016
P50
P577
2012-09-01T00:00:00Z